Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A12 | P48065 | 3/20 | 0.45 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.45 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17934358 | 1.00 | SLC6A12 (0.45) | SLC6A12SLC6A11SLC6A13KDM4EALDH1A1 | |
| SCHEMBL75258 | 1.00 | SLC6A12 (0.45) | SLC6A12SLC6A11SLC6A13KDM4EALDH1A1 | |
| SCHEMBL9887148 | 1.00 | SLC6A12 (0.45) | SLC6A12SLC6A11SLC6A13KDM4EALDH1A1 | |
| SCHEMBL29936790 | 1.00 | SLC6A12 (0.45) | SLC6A12SLC6A11SLC6A13KDM4EALDH1A1 | |
| SCHEMBL560786 | 1.00 | SLC6A12 (0.45) | SLC6A12SLC6A11SLC6A13KDM4EALDH1A1 | |
| SCHEMBL23694121 | 1.00 | SLC6A12 (0.45) | SLC6A12SLC6A11SLC6A13KDM4EALDH1A1 | |
| SCHEMBL17331216 | 1.00 | SLC6A12 (0.45) | SLC6A12SLC6A11SLC6A13KDM4EALDH1A1 | |
| SCHEMBL2380644 | 0.93 | KDM4E (0.40) | SLC6A12SLC6A11SLC6A13KDM4EALDH1A1 | |
| Dimethyl Succinate SCHEMBL29206226 | 0.85 | TSHR (0.39) | SLC6A12SLC6A11SLC6A13KDM4EALDH1A1 | |
| SCHEMBL8464466 | 0.85 | KDM4E (0.42) | KDM4EALDH1A1TDP1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3566750-A2 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | ImmunoGen, Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| US-9999680-B2 | Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents | IMMUNOGEN, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20150359903-A1 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND MAYTANSINOIDS AS CYTOTOXIC AGENTS | IMMUNOGEN, INC. | 2015-12-17 | — | — | US | disclosed |
| US-8859549-B2 | Potassium channel modulators | ABBVIE, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8629143-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20120289500-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2012-11-15 | — | — | US | disclosed |
| US-20110124642-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289500-A1 | POTASSIUM CHANNEL MODULATORS | KCNQ1, KCNQ2, KCNJ2 | SLC6A12 2466/4885SLC6A11 262/4885SLC6A13 396/4885 |
| US-20150359903-A1 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND MAYTANSINOIDS AS CYTOTOXIC AGENTS | ABCB1, CD47, PCNA | SLC6A12 863/4885SLC6A11 521/4885SLC6A13 641/4885 |
| US-20110124642-A1 | POTASSIUM CHANNEL MODULATORS | KCNQ1, KCNQ2, KCNQ3 | SLC6A12 2038/4885SLC6A11 244/4885SLC6A13 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.